Table 1.

Summary of molecular correlative analysis results in GO30140 and IMbrave 150 trials [41].

GO30140 Cohort A: Atezolizumab + Bevacizumab
Gene Alterations or Immune Signatures	Immune Cell Types	TMB
Gene alterations or immune signatures associated with greater response: CD274 (PD-L1 mRNA): high expression associated with longer PFS compared to those with low expression (p = 0.0011). Teff: high expression associated with longer PFS in combination compared to those with low expression (0.0035).	Higher density of CD8+ T associated with better response (p = 0.007).	Greater ORR in TMB-high group (56%) compared to TMB-low group (35%).
Phase III IMbrave 150 Trial: Atezolizumab + Bevacizumab vs. Sorafenib
Gene Alterations or Immune Signatures	Immune Cell Types	TMB
Gene alterations or signatures associated with greater response: CD274 (PD-L1 mRNA): high expression associated with longer PFS in combination group versus sorafenib (p = 0.015), as well as greater OS (0.002) Teff: high expression associated with longer PFS in combination group versus sorafenib (p = 0.047), as well as greater OS (0.0002)	Higher density of intra-tumoral CD8+ T cells showed longer PFS (0.053) and OS (0.001) Low ratio of Treg/Teff signatures had higher PFS and OS compared to sorafenib Higher density of CD8+ T cells associated with longer OS and PFS compared with sorafenib	No associations of TMB with outcome
GO30140 Cohort F: Atezolizumab + Bevacizumab vs. Atezolizumab
Gene Alterations or Immune Signatures	Blood Vessel Density
Genes or signatures associated with greater response: Myeloid inflammation: high expression associated with greater PFS (p = 0.036 versus monotherapy Gene signatures of Teff: high expression associated with greater PFS (p = 0.034 versus monotherapy KDR (VEGF receptor 2): high expression associated with greater PFS in combination group compared to monotherapy (p = 0.011)	High vessel density in baseline tumors associated with longer PFS in combination group compared to monotherapy (p = 0.0018)